Pfizer seeks approval for emergency use of Covid-19 vaccine in the US in November


(Reuters) – Pfizer said on Friday it could apply for approval for the emergency use in the United States of its Covid-19 combat vaccine candidate, which is being developed together with Germany’s BioNTech SE, as soon as a safety milestone is reached in the third week of November.

The US drug regulatory agency, FDA, said it wanted at least two months of safety data before authorizing the emergency use of any experimental coronavirus vaccine.

Based on the current test enrollment and dosing rate, Pfizer expects to have this safety data in the third week of November, said executive director Albert Bourla in a statement.

Pfizer had previously said it expected final-stage test data in October.

(Por Manojna Maddipatla e Manas Mishra em Bengaluru)

InfoMoney Newsletter
Information, analysis and recommendations that are worth money, every day in your email:


Please enter your comment!
Please enter your name here